About Sangamo Therapeutics
Sangamo Therapeutics (NASDAQ:SGMO) is a biotechnology company focused on developing genomic medicine. Its research and development efforts are aimed at delivering transformative therapies for a broad range of diseases, including genetic disorders, cancer, and diseases linked to the central nervous system. Utilizing cutting-edge technologies such as gene editing and gene therapy, Sangamo is pioneering treatments that have the potential to provide long-lasting effects for patients worldwide. The company's ambitious projects involve developing treatments that address the underlying causes of diseases at the genetic level, with the objective of providing significant and enduring health benefits. Through collaboration with industry partners and a robust in-house pipeline, Sangamo is committed to advancing healthcare and improving the quality of life for patients with unmet medical needs.
Snapshot
Operations
Produtos e/ou serviços de Sangamo Therapeutics
- Zynteglo, a gene therapy for treating beta thalassemia, utilizes a lentiviral vector to add a functional copy of the ß-globin gene into a patient's hematopoietic stem cells.
- ST-400, a gene-edited cell therapy aimed at treating beta thalassemia, involves editing a patient's own hematopoietic stem cells to overcome the effects of the disease.
- SB-525, a gene therapy for Hemophilia A, uses an adeno-associated virus to deliver a functional copy of the Factor VIII gene to the patient's liver cells.
- TX200, a CAR Treg cell therapy aimed at preventing immune rejection in organ transplantation, especially in HLA-A2 kidney transplants, by engineering regulatory T cells.
- BIVV003, a collaboration project with Bioverativ for the development of a gene-edited cell therapy for sickle cell disease, aiming to increase the production of fetal hemoglobin in patient's cells.
- PF-07055480 (formerly SB-FIX), a hemophilia B treatment using gene editing tools to insert a corrected version of the Factor IX gene directly into the patient's liver cells.
equipe executiva do Sangamo Therapeutics
- Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.CEO, President & Director
- Ms. Prathyusha Duraibabu CPA, M.B.A.Interim Principal Financial Officer
- Mr. Scott B. WilloughbySenior VP, Chief Legal Officer & Corporate Secretary
- Dr. Nathalie Dubois-Stringfellow Ph.D.Senior VP & Chief Development Officer
- Mr. Nikunj JainVP of Finance, Corporate Controller & Principal Accounting Officer
- Mr. Gregory Davis Ph.D.Head of Research & Technology
- Ms. Louise WilkieHead of Global Corporate Communications & Investor Relations
- Mr. Phillip RamseyChief Technical Officer
- Ms. Stephanie J. Seiler CLPVP and Head of Business Development & Alliance Management
- Mr. David OjalaScientist II - Discovery & Translational Research